Loading...

Darcy Spicer, MD

Title(s)Associate Professor of Clinical Medicine
Phone+1 323 865 3904
vCardDownload vCard
    Other Positions
    Title(s)Chief, Division of Oncology, Department of Medicine

    Title(s)Co-Director, Lynne Cohen Clinic


    Collapse Overview 
    Collapse Overview
    Dr. Spicer has been on faculty at the Keck School of Medicine at USC since 1980 when he began as a Clinical Instructor of Medicine in the Department of Oncology. Dr. Spicer holds several United States patents for his medical inventions. He is a medical oncology attending physician at both the LAC+USC Medical Center and the USC Norris Comprehensive Cancer Center.

    Collapse Research 
    Collapse Research Activities and Funding
    SCCISARS 2: An e-Solution to Protect Human Subjects
    NIH/NCRR S07RR018274Sep 1, 2002 - Aug 31, 2006
    Role: Principal Investigator
    GNRH AGONIST REGIMEN FOR BREAST CANCER PREVENTION
    NIH/NCI U01CA079428Sep 15, 1998 - Aug 31, 2000
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sweeney FC, Demark-Wahnefried W, Courneya KS, Sami N, Lee K, Tripathy D, Yamada K, Buchanan TA, Spicer DV, Bernstein L, Mortimer JE, Dieli-Conwright CM. Aerobic and Resistance Exercise Improves Shoulder Function in Women Who Are Overweight or Obese and Have Breast Cancer: Randomized, Controlled Trial. Phys Ther. 2019 Jul 16. PMID: 31309977.
      View in: PubMed
    2. Lee K, Tripathy D, Demark-Wahnefried W, Courneya KS, Sami N, Bernstein L, Spicer D, Buchanan TA, Mortimer JE, Dieli-Conwright CM. Effect of Aerobic and Resistance Exercise Intervention on Cardiovascular Disease Risk in Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 May 01; 5(5):710-714. PMID: 30920602.
      View in: PubMed
    3. Dieli-Conwright CM, Sweeney FC, Courneya KS, Tripathy D, Sami N, Lee K, Buchanan TA, Spicer D, Bernstein L, Mortimer JE, Demark-Wahnefried W. Hispanic ethnicity as a moderator of the effects of aerobic and resistance exercise in survivors of breast cancer. Cancer. 2019 Mar 15; 125(6):910-920. PMID: 30500981.
      View in: PubMed
    4. Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Sweeney FC, Stewart C, Buchanan TA, Spicer D, Tripathy D, Bernstein L, Mortimer JE. Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial. Breast Cancer Res. 2018 10 19; 20(1):124. PMID: 30340503.
      View in: PubMed
    5. D'Souza A, Spicer D, Lu J. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. J Hematol Oncol. 2018 06 11; 11(1):80. PMID: 29891002.
      View in: PubMed
    6. Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, Spicer D, Tripathy D, Bernstein L, Mortimer JE. Reply to E. Parkin et al. J Clin Oncol. 2018 07 10; 36(20):2129-2130. PMID: 29847294.
      View in: PubMed
    7. Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, Spicer DV, Tripathy D, Bernstein L, Mortimer JE. Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018 03 20; 36(9):875-883. PMID: 29356607.
      View in: PubMed
    8. Dieli-Conwright CM, Parmentier JH, Sami N, Lee K, Spicer D, Mack WJ, Sattler F, Mittelman SD. Adipose tissue inflammation in breast cancer survivors: effects of a 16-week combined aerobic and resistance exercise training intervention. Breast Cancer Res Treat. 2018 Feb; 168(1):147-157. PMID: 29168064.
      View in: PubMed
    9. Agarwal SK, Daniels A, Drosman SR, Udoff L, Foster WG, Pike MC, Spicer DV, Daniels JR. Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone. Biomed Res Int. 2015; 2015:934164. PMID: 26881208.
      View in: PubMed
    10. Wu AH, Spicer D, Garcia A, Tseng CC, Hovanessian-Larsen L, Sheth P, Martin SE, Hawes D, Russell C, MacDonald H, Tripathy D, Su MY, Ursin G, Pike MC. Double-Blind Randomized 12-Month Soy Intervention Had No Effects on Breast MRI Fibroglandular Tissue Density or Mammographic Density. Cancer Prev Res (Phila). 2015 Oct; 8(10):942-51. PMID: 26276750.
      View in: PubMed
    11. Yu SS, Spicer DV, Hawes D, Tseng CC, Yang CS, Pike MC, Wu AH. Biological effects of green tea capsule supplementation in pre-surgery postmenopausal breast cancer patients. Front Oncol. 2013; 3:298. PMID: 24380073.
      View in: PubMed
    12. Wu AH, Spicer DV, Pike MC. Soy isoflavones for breast cancer risk reduction. Cancer Prev Res (Phila). 2012 Jul; 5(7):984-5; author reply 986-7. PMID: 22693167.
      View in: PubMed
    13. Hovanessian-Larsen L, Taylor D, Hawes D, Spicer DV, Press MF, Wu AH, Pike MC, Pearce CL. Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. Contraception. 2012 Sep; 86(3):238-43. PMID: 22325110.
      View in: PubMed
    14. Wu AH, Spicer D, Stanczyk FZ, Tseng CC, Yang CS, Pike MC. Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women. Cancer Prev Res (Phila). 2012 Mar; 5(3):393-402. PMID: 22246619.
      View in: PubMed
    15. Chung K, Hovanessian-Larsen LJ, Hawes D, Taylor D, Downey S, Spicer DV, Stanczyk FZ, Patel S, Anderson AR, Pike MC, Wu AH, Pearce CL. Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation. Breast Cancer Res Treat. 2012 Apr; 132(2):653-60. PMID: 22083231.
      View in: PubMed
    16. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011 Nov 20; 29(33):4373-80. PMID: 22010008.
      View in: PubMed
    17. Lee E, Nichols P, Groshen S, Spicer D, Lee AS. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer. 2011 Feb 01; 128(3):726-31. PMID: 20473863.
      View in: PubMed
    18. Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, Schneider RJ, Pietenpol JA, Formenti SC. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat. 2010 Dec; 124(3):723-32. PMID: 20878462.
      View in: PubMed
    19. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009 May 01; 27(13):2163-9. PMID: 19307510.
      View in: PubMed
    20. Taylor D, Pearce CL, Hovanessian-Larsen L, Downey S, Spicer DV, Bartow S, Pike MC, Wu AH, Hawes D. Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast. Breast Cancer Res Treat. 2009 Nov; 118(1):161-8. PMID: 19205874.
      View in: PubMed
    21. Wu AH, Pike MC, Williams LD, Spicer D, Tseng CC, Churchwell MI, Doerge DR. Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. J Clin Oncol. 2007 Jul 20; 25(21):3024-30. PMID: 17536081.
      View in: PubMed
    22. Weitzel JN, Buys SS, Sherman WH, Daniels A, Ursin G, Daniels JR, MacDonald DJ, Blazer KR, Pike MC, Spicer DV. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):654-8. PMID: 17255289.
      View in: PubMed
    23. Pike MC, Wu AH, Spicer DV, Lee S, Pearce CL. Estrogens, progestins, and risk of breast cancer. Ernst Schering Found Symp Proc. 2007; (1):127-50. PMID: 18540571.
      View in: PubMed
    24. Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 2006 Aug 15; 66(16):7849-53. PMID: 16912156.
      View in: PubMed
    25. ten Tije AJ, Synold TW, Spicer D, Verweij J, Doroshow JH, Sparreboom A. Effect of valspodar on the pharmacokinetics of unbound paclitaxel. Invest New Drugs. 2003 Aug; 21(3):291-8. PMID: 14578679.
      View in: PubMed
    26. Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol. 2003 Mar 01; 21(5):864-70. PMID: 12610186.
      View in: PubMed
    27. Formenti SC, Spicer D, Skinner K, Cohen D, Groshen S, Bettini A, Naritoku W, Press M, Salonga D, Tsao-Wei D, Danenberg K, Danenberg P. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2002 Feb 01; 52(2):397-405. PMID: 11872285.
      View in: PubMed
    28. Gram IT, Ursin G, Spicer DV, Pike MC. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol Biomarkers Prev. 2001 Nov; 10(11):1117-20. PMID: 11700258.
      View in: PubMed
    29. Ursin G, Parisky YR, Pike MC, Spicer DV. Mammographic density changes during the menstrual cycle. Cancer Epidemiol Biomarkers Prev. 2001 Feb; 10(2):141-2. PMID: 11219771.
      View in: PubMed
    30. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer. 2000 Jun; 7(2):73-83. PMID: 10903525.
      View in: PubMed
    31. Spicer DV, Pike MC. Future possibilities in the prevention of breast cancer: luteinizing hormone-releasing hormone agonists. Breast Cancer Res. 2000; 2(4):264-7. PMID: 11250719.
      View in: PubMed
    32. Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, Synold T, Moran R. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol. 2000; 45(2):103-10. PMID: 10663624.
      View in: PubMed
    33. Pike MC, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol. 1998 Apr 15; 147(8):718-21. PMID: 9554412.
      View in: PubMed
    34. Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV. The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev. 1998 Jan; 7(1):43-7. PMID: 9456242.
      View in: PubMed
    35. Spicer DV, Ursin G, Pike MC. Progesterone concentrations--physiologic or pharmacologic? Fertil Steril. 1996 May; 65(5):1077-8. PMID: 8612843.
      View in: PubMed
    36. Pike MC, Ursin G, Spicer DV. Experiments on proliferation of normal human breast tissue in nude mice do not show that progesterone does not stimulate breast cells. Endocrinology. 1996 Apr; 137(4):1505-6. PMID: 8625931.
      View in: PubMed
    37. Ursin G, Pike MC, Spicer DV, Porrath SA, Reitherman RW. Can mammographic densities predict effects of tamoxifen on the breast? J Natl Cancer Inst. 1996 Jan 17; 88(2):128-9. PMID: 8537975.
      View in: PubMed
    38. Turrill M, Spicer DV, Kelley AS, Herman RL, Russell CA, Muggia FM. Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma. Cancer Invest. 1995; 13(2):160-4. PMID: 7874569.
      View in: PubMed
    39. Spicer DV, Krecker EA, Pike MC. The endocrine prevention of breast cancer. Cancer Invest. 1995; 13(5):495-504. PMID: 7552817.
      View in: PubMed
    40. Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst. 1994 Mar 16; 86(6):431-6. PMID: 8120917.
      View in: PubMed
    41. Ursin G, Spicer DV, Pike MC. Contraception and cancer prevention. Adv Contracept Deliv Syst. 1994; 10(3-4):369-86. PMID: 12287845.
      View in: PubMed
    42. Spicer DV, Pike MC. Sex steroids and breast cancer prevention. J Natl Cancer Inst Monogr. 1994; (16):139-47. PMID: 7999456.
      View in: PubMed
    43. Spicer DV, Pike MC. Breast cancer prevention through modulation of endogenous hormones. Breast Cancer Res Treat. 1993 Nov; 28(2):179-93. PMID: 8173070.
      View in: PubMed
    44. Spicer DV, Pike MC. Hormone replacement after breast cancer. Lancet. 1993 Jul 17; 342(8864):183-4. PMID: 8101287.
      View in: PubMed
    45. Spicer DV, Pike MC, Pike A, Rude R, Shoupe D, Richardson J. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception. 1993 May; 47(5):427-44. PMID: 8390340.
      View in: PubMed
    46. Ursin G, Spicer DV, Pike MC. Tamoxifen and prevention. Lancet. 1993 Mar 13; 341(8846):693-4; author reply 695. PMID: 8095598.
      View in: PubMed
    47. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993; 15(1):17-35. PMID: 8405201.
      View in: PubMed
    48. Pike MC, Spicer DV. The chemoprevention of breast cancer by reducing sex steroid exposure: perspectives from epidemiology. J Cell Biochem Suppl. 1993; 17G:26-36. PMID: 8007706.
      View in: PubMed
    49. Spicer DV, Kelley A, Herman R, Dean G, Stevenson L, Mitchell MS. Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer. Cancer Immunol Immunother. 1992; 34(6):424-6. PMID: 1532923.
      View in: PubMed
    50. Spicer DV, Pike MC. The prevention of breast cancer through reduced ovarian steroid exposure. Acta Oncol. 1992; 31(2):167-74. PMID: 1622631.
      View in: PubMed
    51. Spicer DV, Shoupe D, Pike MC. GnRH agonists as contraceptive agents: predicted significantly reduced risk of breast cancer. Contraception. 1991 Sep; 44(3):289-310. PMID: 1662596.
      View in: PubMed
    52. Spicer DV, Pike MC, Henderson BE. Ovarian cancer and long-term tamoxifen in premenopausal women. Lancet. 1991 Jun 08; 337(8754):1414. PMID: 1674785.
      View in: PubMed
    53. Spicer DV, Pike MC, Henderson BE, Groshen S. Tamoxifen and estrogen replacement therapy as agents of disease prevention. J Natl Cancer Inst. 1991 Jan 02; 83(1):63-4. PMID: 1984521.
      View in: PubMed
    54. Grunberg SM, Clay C, Spicer DV. Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer. Sel Cancer Ther. 1991; 7(1):17-21. PMID: 1833803.
      View in: PubMed
    55. Spicer DV, Ardalan B, Daniels JR, Silberman H, Johnson K. Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res. 1988 Jan 15; 48(2):459-61. PMID: 3335014.
      View in: PubMed